News | March 13, 2025
Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The MDR certification reafirms that these products meet the highest safety, quality, and regulatory standards
This MoU marks a significant milestone in interdisciplinary research, paving the way for scientific advancements in homoeopathy
Overall investment in the US facility is estimated around US$50 million
Vidya will spark conversations around less discussed and important aspects of health, including intimate care and sleep issues
This e-commerce platform is launched as a hyperlocal model
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
Subscribe To Our Newsletter & Stay Updated
